

	Type	L #	Hits	Search Text	Dbs	Time Stamp	Comments	Error Definition	Error
1	BRS	L1	126	(glucagon\$1like adj peptide-2) or glp-2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/3 1 19:00			0
2	BRS	L3	545	(glucagon\$1like adj peptide\$12) or glp-2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/3 1 19:01			0
3	BRS	L4	41923	phosphate adj buffer	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/3 1 19:01			0
4	BRS	L5	28864	histidine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/3 1 19:01			0
5	BRS	L6	10729	(bulking adj agent) or mannitol or sucrose	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/3 1 19:02			0
6	BRS	L7	2	3 same (phosphate adj buffer) same histidine same ((bulking adj agent) or mannitol or sucrose)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/3 1 19:18			0
7	BRS	L8	3	(glp-2 adj receptor) same antagonist	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/3 1 19:19			0
8	BRS	L9	0	((glucagon adj like adj peptide adj "2") or glp-2) same lyophiliz\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/3 1 19:21			0
9	BRS	L10	1	isaacs adj indu.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/3 1 19:22			0

	Type	L #	Hits	Search Text	Dbs	Time Stamp	Comments	Error Definition	Error
1	BRS	L1	2	((glucagon\$1like adj peptide\$12) or glp-2) same (phosphate adj buffer) same histidine same ((bulking adj agent) or mannitol or sucrose)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/02/01 09:27			0
2	BRS	L2	41923	phosphate adj buffer	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/02/01 09:25			0
3	BRS	L3	28864	histidine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/02/01 09:25			0
4	BRS	L4	10729	(bulking adj agent) or mannitol or sucrose	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/02/01 09:25			0
5	BRS	L5	3	(glp-2 adj receptor) same antagonist	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/02/01 09:26			0
6	BRS	L6	0	(glucagon\$1like adj peptide\$12 adj receptor) same antagonist	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/02/01 09:27			0
7	BRS	L7	0	2 same 3 same 4 same 5	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/02/01 09:28			0
8	BRS	L8	1	kit same 1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/02/01 09:28			0

FILE 'HOME' ENTERED AT 09:30:16 ON 01 FEB 2003

=> file medline caplus biosis embase scisearch agricola		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 09:30:44 ON 01 FEB 2003

FILE 'CAPLUS' ENTERED AT 09:30:44 ON 01 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:30:44 ON 01 FEB 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 09:30:44 ON 01 FEB 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 09:30:44 ON 01 FEB 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 09:30:44 ON 01 FEB 2003

=> s (glucagon-like peptide-2) or glp-2
L1 1196 (GLUCAGON-LIKE PEPTIDE-2) OR GLP-2

=> s phosphate buffer
L2 74830 PHOSPHATE BUFFER

=> s histidine
L3 156212 HISTIDINE

=> s (bulking agent) or mannitol or sucrose
L4 364324 (BULKING AGENT) OR MANNITOL OR SUCROSE

=> s (glucagon-like peptide-2 receptor) or (glp-2 receptor)
L5 142 (GLUCAGON-LIKE PEPTIDE-2 RECEPTOR) OR (GLP-2 RECEPTOR)

=> s l5 (p) antagonist
L6 8 L5 (P) ANTAGONIST

=> s (l1 or l6) (p) l3 (p) l4 (p) l5
L7 0 (L1 OR L6) (P) L3 (P) L4 (P) L5

=> s kit (p) (l1 or l5)
L8 3 KIT (P) (L1 OR L5)

=> duplicate remove l8
DUPLICATE PREFERENCE IS 'CAPLUS, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L8
L9 3 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)

=> d l9 1-3 ibib abs

L9 ANSWER 1 OF 3 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2000:461256 BIOSIS
DOCUMENT NUMBER: PREV200000461256
TITLE: Methods of enhancing functioning of the upper
gastrointestinal tract.
AUTHOR(S): Drucker, Daniel J. (1)
CORPORATE SOURCE: (1) Ontario Canada
ASSIGNEE: 1149336 Ontario Inc., Toronto, Canada
PATENT INFORMATION: US 6051557 April 18, 2000
SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (Apr. 18, 2000) Vol. 1233, No. 3, pp. No
pagination. e-file.

DOCUMENT TYPE: Patent
 LANGUAGE: English

AB The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the upper gastrointestinal tract including the esophagus and stomach. In particular, it has now been demonstrated that ***GLP*** - ***2*** and peptidic agonists of ***GLP*** - ***2*** can cause proliferation of the tissue of the upper gastrointestinal tract. Thus, the invention provides methods of proliferating the upper gastrointestinal tract in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the upper gastrointestinal tract, including inflammatory diseases. ***GLP*** - ***2*** stimulates the growth of upper gastrointestinal tissue when administered in conjunction with other peptide hormones. The invention further provides pharmaceutical compositions of ***GLP*** - ***2*** with at least one other peptide hormone, methods of enhancing the growth of upper gastrointestinal tissue and of gastrointestinal disorders by increasing serum levels of ***GLP*** - ***2*** and at least one other peptide hormone, and ***kits*** for performing the methods of the invention.

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:789042 CAPLUS

DOCUMENT NUMBER: 130:43339

TITLE: Glucagon-like peptide 2 formulations for enhancing functioning of the upper gastrointestinal tract

INVENTOR(S): Drucker, Daniel J.

PATENT ASSIGNEE(S): 1149336 Ontario Inc., Can.

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9852600	A1	19981126	WO 1998-CA497	19980515
W:				
AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6051557	A	20000418	US 1998-59504	19980413
AU 9875163	A1	19981211	AU 1998-75163	19980515
AU 746633	B2	20020502		
EP 981362	A1	20000301	EP 1998-922546	19980515
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9808804	A	20010918	BR 1998-8804	19980515
JP 2002502369	T2	20020122	JP 1998-549741	19980515
PRIORITY APPLN. INFO.:			US 1997-46754P	P 19970516
			GB 1997-15481	A 19970723
			US 1998-59504	A 19980413
			WO 1998-CA497	W 19980515

AB The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the upper gastrointestinal tract including the esophagus and stomach. In particular, it has now been demonstrated that ***GLP*** - ***2*** and peptidic agonists of ***GLP*** - ***2*** can cause proliferation of the tissue of the upper gastrointestinal tract. Thus, the invention provides methods of proliferating the upper gastrointestinal tract in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the upper gastrointestinal tract, including inflammatory diseases. ***GLP*** - ***2*** stimulates the growth of upper gastrointestinal tissue when administered in conjunction with other peptide hormones. The invention further provides pharmaceutical compns. of ***GLP*** - ***2*** with at least one other peptide hormone, methods of enhancing the growth of upper

gastrointestinal tissue and of gastrointestinal disorders by increasing serum levels of ***GLP*** - ***2*** and at least one other peptide hormone, and ***kits*** for performing the methods of the invention.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:402335 CAPLUS
DOCUMENT NUMBER: 129:77032
TITLE: Compositions containing glucagon-related peptides in combination with other agents for enhancing intestinal function
INVENTOR(S): Drucker, Daniel J.
PATENT ASSIGNEE(S): 1149336 Ontario Inc., Can.; Drucker, Daniel J.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825644	A1	19980618	WO 1997-CA945	19971210
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5952301	A	19990914	US 1996-763177	19961210
AU 9852200	A1	19980703	AU 1998-52200	19971210
EP 944396	A1	19990929	EP 1997-946986	19971210
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
PRIORITY APPLN. INFO.:			US 1996-763177	19961210
			WO 1997-CA945	19971210

AB ***GLP*** - ***2*** stimulates the growth of both small intestine and large intestine tissue when administered in conjunction with other agents. The invention provides pharmaceutical compns. of ***GLP*** - ***2*** with at least one other agent that increase the biol. activity of ***GLP*** - ***2***, methods of enhancing the growth of both small and large intestine tissue and of ameliorating nutritional or gastrointestinal disorders by increasing serum levels of ***GLP*** - ***2*** and at least one other agent, and ***kits*** for performing the methods of the invention.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 09:30:16 ON 01 FEB 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 09:30:44 ON 01 FEB 2003

L1 1196 S (GLUCAGON-LIKE PEPTIDE-2) OR GLP-2
L2 74830 S PHOSPHATE BUFFER
L3 156212 S HISTIDINE
L4 364324 S (BULKING AGENT) OR MANNITOL OR SUCROSE
L5 142 S (GLUCAGON-LIKE PEPTIDE-2 RECEPTOR) OR (GLP-2 RECEPTOR)
L6 8 S L5 (P) ANTAGONIST
L7 0 S (L1 OR L6) (P) L3 (P) L4 (P) L5
L8 3 S KIT (P) (L1 OR L5)
L9 3 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	53.75	53.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOT

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.30

-1.30

STN INTERNATIONAL LOGOFF AT 09:36:01 ON 01 FEB 2003